Overall survival was significantly better in patients with SIX3-high expression group than in those with SIX3 low expression group in all patients with lung adenocarcinomas (Fig. 6a, p = 0.005), stage I patients (Fig. 6b, p = 0.008), and patients with BAC features (Fig. 6c, p = 0.01). Here, SIX3 is linked to minimally invasive lung adenocarcinoma.